688488 艾迪药业
2025/122024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-2.008-13.407-6.545-9.893-2.246
总资产报酬率 ROA (%)-1.033-7.810-4.472-8.032-2.081
投入资产回报率 ROIC (%)-1.273-9.201-5.052-8.871-2.198

边际利润分析
销售毛利率 (%)66.79254.93346.19542.90133.191
营业利润率 (%)6.686-39.364-22.376-58.175-17.143
息税前利润/营业总收入 (%)5.334-36.632-19.843-58.139-17.375
净利润/营业总收入 (%)1.124-33.230-18.492-50.812-11.726

收益指标分析
经营活动净收益/利润总额(%)127.03678.84396.92891.603123.454
价值变动净收益/利润总额(%)70.958-10.678-15.376-11.805-19.142
营业外收支净额/利润总额(%)-95.1340.9230.0400.218-3.697

偿债能力分析
流动比率 (X)1.3241.3791.7752.4198.936
速动比率 (X)0.9580.9861.3991.9497.701
资产负债率 (%)43.88642.92335.55727.5788.700
带息债务/全部投入资本 (%)34.15031.14023.71913.326-0.187
股东权益/带息债务 (%)181.812207.807305.446617.002-52,227.997
股东权益/负债合计 (%)114.929122.234181.238262.6081,049.375
利息保障倍数 (X)2.796-11.822-7.805-356.43520.612

营运能力分析
应收账款周转天数 (天)72.723138.534129.628126.837126.673
存货周转天数 (天)387.756420.481277.339349.064213.182